Oxytocin & PWS Program

About OT4B

OT4B is a private, patient-founded biotech company based in Paris, France, dedicated to developing oxytocin for Prader-Willi syndrome, a rare genetic disorder. The company is advancing a clinical development program in partnership with Toulouse University Hospital, built upon over a decade of academic research. Its strategy targets the severe neonatal phase of PWS first, aiming to improve feeding, behavior, and social interaction disorders, with the goal of making a treatment accessible to patients as soon as possible. OT4B represents a unique model of patient community-driven drug development for a high-unmet-need rare disease.

About OT4B

OT4B is a private, patient-founded biotech company based in Paris, France, dedicated to developing oxytocin for Prader-Willi syndrome, a rare genetic disorder. The company is advancing a clinical development program in partnership with Toulouse University Hospital, built upon over a decade of academic research. Its strategy targets the severe neonatal phase of PWS first, aiming to improve feeding, behavior, and social interaction disorders, with the goal of making a treatment accessible to patients as soon as possible. OT4B represents a unique model of patient community-driven drug development for a high-unmet-need rare disease.

Therapeutic Areas